UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.
The University of Manchester researchers, who were funded by the charity Leukaemia & Lymphoma Research, have shown that, when used in conjunction with radiotherapy, the new drug is potentially four times more likely to lead to long-term survival than radiotherapy alone.
Relapse is a common fate for many lymphoma patients and new treatments are desperately needed. The new research, which is published online in Blood, the Journal of the American Society of Hematology (ASH), shows that the chemical R848 can be used to prime the immune system to fight cancer.
R848 is a chemical which signals to certain molecules known as receptors found on the surface of immune cells, triggering them into action. Receptors play a key role in the function of the immune cell by recognising harmful agents and instructing the cell to respond. It was shown that injections of R848 can generate a rapid expansion of specific anti-lymphoma immune cells known as 'killer T cells'.
Dr Simon Dovedi, of the University of Manchester's School of Cancer and Enabling Sciences, who led the research, said: "Excitingly we think that R848 could be capable of giving patients a protective immunological memory by generating lymphoma-specific anti-tumour cells. This could be the key to ensuring long-term survival."
The Manchester team tested injections of R848, in combination with radiotherapy, in the laboratory on mice with lymphoma. It was found to have few side effects, with 100% of mice achieving long-term survival compared to just 28% of those mice which were treated with radiotherapy alone. In those mice that achieved long-term survival through treatment with R848 and radiotherapy, any re-introduction of cancer was completely rejected by the immune system in 75% of cases. These successful laboratory results mean that it could soon be used in early phase clinical trials for patients with lymphoma.
Professor Chris Bunce, Research Director of Leukaemia & Lymphoma Research, said: "While it is still early and this treatment has not yet been tested in humans, these results are hugely promising. One of the major obstacles to long-term successful treatment for many types of lymphoma has been relapse after initial successful treatment. Treatment with R848 can prime T cells to recognise various tumour-associated antigens, protecting patients from the return of the cancer."
For further information contact:
Leukaemia & Lymphoma Research Press Office
44 20 7269 9019
press mobile 44 7824 375880
Notes to editors:
The report is published online in the journal Blood, the Journal of the American Society of Hematology (ASH), under the title 'Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma'. Principal authors: Dr Simon Dovedi, Dr Jamie Honeychurch and Professor Tim Illidge of The School of Cancer and Enabling Sciences, University of Manchester
Leukaemia & Lymphoma Research is dedicated to saving the lives of blood cancer patients through the promotion and assistance of research into causes, diagnosis and treatment. We are committed to advancing the interests of patients and increasing public understanding of blood cancers.
Around 30,000 people of all ages, from children and teenagers to adults are diagnosed with blood cancers like leukaemia, lymphoma and myeloma in the UK every year.
We receive no government funding and rely entirely on voluntary support. In the next five years we need to raise £120 million to continue our lifesaving work. Further information, including patient information booklets, is available from http://www.llresearch.org.uk/ beatingbloodcancers.org.uk or on 020 7405 0101.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.